Bayesian Belief Network for Clinical Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for thyroid nodules, transplant glomerulopathy, acute traumatic wound healing, and breast cancer risk are inadequate due to high variability, subjectivity, and inefficiency, leading to unnecessary surgeries and inadequate risk assessment.
Innovation Solution
A fully unsupervised machine-learned Bayesian Belief Network model that utilizes clinical parameters to provide patient-specific risk assessments and predictive tools for malignancy, wound healing, and breast cancer, integrating multiple clinical variables and updating continuously for improved decision support.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods (FNAB, ultrasound, TSH levels) are used for thyroid nodule evaluation, then diagnostic procedures can be performed with existing tools, but diagnostic accuracy is insufficient leading to high variability and subjectivity in determining malignancy risk
Solution Approach 1:
The patent transforms qualitative diagnostic assessments into quantitative measurements by implementing a Bayesian Belief Network that calculates specific probability values (0-100%) for malignancy risk. The system processes multiple clinical parameters (TSH levels, nodule size, ultrasound features, patient demographics) and converts them into a unified quantitative risk score, eliminating subjectivity and variability inherent in traditional diagnostic methods.
Solution Approach 2:
The patent introduces a Bayesian Belief Network model as an intermediary computational system between clinical observations and diagnostic conclusions. This model acts as a mediator that systematically integrates multiple clinical parameters through probabilistic reasoning, providing an objective bridge between raw clinical data and malignancy risk assessment, thereby reducing diagnostic variability.
2Measurement precision
If FNAB is performed on all nodules with suspicious features or size >1.0-1.5 cm, then malignancy detection sensitivity increases, but unnecessary surgeries increase because the majority of nodules are benign
Solution Approach 1:
The patent applies partial action by selectively recommending FNAB only for nodules that meet specific high-risk criteria defined by the Bayesian model (typically probability >50-70% depending on clinical context). Instead of performing FNAB on all nodules with suspicious features, the system identifies and targets only those with sufficiently high predicted malignancy risk, thereby reducing unnecessary biopsies and subsequent surgeries while maintaining high detection sensitivity for actual malignancies.
Solution Approach 2:
The patent implements feedback by continuously updating the Bayesian Bellet Network with new clinical data, FNAB results, and surgical outcomes. This feedback loop refines the probability calculations and risk thresholds over time, improving the system's ability to accurately distinguish between benign and malignant nodules, thereby further reducing unnecessary invasive procedures while maintaining high malignancy detection rates.
3Reliability
If indeterminate FNA cytology results are obtained in 20% of cases, then diagnostic thoroughness is maintained, but diagnostic efficiency decreases leading to increased thyroid resection frequency
Solution Approach 1:
The patent applies preliminary action by performing the Bayesian risk assessment calculation before proceeding to FNAB or surgery. The model pre-evaluates all available clinical parameters (demographics, TSH levels, ultrasound characteristics, nodule size) to generate an initial malignancy probability estimate. This preliminary assessment guides subsequent diagnostic steps, allowing clinicians to avoid FNAB in clearly low-risk cases and to prioritize FNAB in high-risk cases, thereby improving diagnostic efficiency while maintaining thoroughness.
Solution Approach 2:
The patent segments the diagnostic population into distinct risk stratification groups based on Bayesian probability thresholds (e.g., low risk <20%, intermediate 20-50%, high risk >50%). This segmentation allows different diagnostic and management pathways to be applied to different segments of the patient population, improving overall diagnostic efficiency by avoiding unnecessary workup in low-risk segments while maintaining high diagnostic thoroughness in high-risk segments.
Data Source
AI summary
An embodiment of the invention provides a method for determining a patient-specific probability of disease. The method collects clinical parameters from a plurality of patients to create a training database. A fully unsupervised Bayesian Belief Network model is created using data from the training database; and, the fully unsupervised Bayesian Belief Network is validated. Clinical parameters are collected from an individual patient; and, such clinical parameters are input into the fully unsupervised Bayesian Belief Network model via a graphical user interface. The patient-specific probability of the healing rate of an acute traumatic wound is output from the fully unsupervised Bayesian Belief Network model and sent to the graphical user interface for use by a clinician in pre-operative planning. The fully unsupervised Bayesian Belief Network model is updated using the clinical parameters from the individual patient and the patient-specific probability of the healing rate of an acute traumatic wound.